Welcom to Sichuan Hengkang Science and Technology Development Co.,Ltd.

With the release of companies’ 2021 financial results, the sales list of multiple sclerosis (MS) drugs in 2021 is also released, as listed in the table below.It is worth mentioning that the MS sector has now seen six blockbuster products with sales of more than $1 billion.
CFCe4
Roche’s CD20 mmab Ocrevus topped the list, with sales of 5.055 billion Swiss francs (about $5.474 billion) in 2021.

Novartis’s sphingosine 1-phosphate (S1PR) receptor modulator Gilenya sales declined, but it remained in second place.It is worth mentioning that the US Court of Appeals for the Federal Circuit (CAFC) upheld the Novartis Gilenya patent ruling in 2022, and that Gilenya generic drugs will not be listed in the US market for the next two years.

Sanofi’s Aubagio ranked third with sales of 1.955 billion euros, but also saw a slight decline in 2021.Despite its approval by the EC in June 2021 for first-line treatment of pediatric patients with relapsed-remission multiple sclerosis (RRMS) aged 10 – 17 years, making it the first EU-approved oral therapy for children and adolescents with MS.Moreover, the approval will provide the Aubagio with an additional year of market protection in the EU.

Boogen’s annual Tysabri 2021 sales rose to $2.063.1 billion, ranking fourth.The drug is a recombinant humanized IgG4 monoclonal antibody capable of binding 4 subunits of 41 and 47 integral proteins expressed on the surface of all leukocytes except neutrophils, which rely on 4-intact proteins to adhere to receptors on endothelial cells to enter the tissue.In April 2021, the drug was approved by the EC to treat relapsing-remitting multiple sclerosis (MS), but was rejected in the United States.Approval of subcutaneous preparations will expand the clinical context of Tysabri for treatment outside the infusion center.Moreover, subcutaneous administration is shorter than intravenous preparations and allows the physician to clinically appropriately shorten or cancel the post-observation period after 6 doses of treatment in some patients.

Sales of Bojian’s Tecfidera fell significantly with patent expiration and upgraded Vumerity, down from $3.841 billion in 2020 to $1.952 billion in 2021.Sales of its upgraded product, Vumerity, could not offset Tecfidera’s declining sales.

In addition, sales of approved MS drugs such as CD20 mmab Kesimpta, SIPR regulator Mayzent and Zeposia have remained growing in recent years.J & Johnson also owns an S1PR regulator, ——Ponvory (ponesimod).The drug was approved by the FDA and EMA in March and May 2021 for the treatment of adult patients with recurrent multiple sclerosis (MS), including clinical isolated syndrome (CIS), relapse-remission multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). No specific sales have been reported.

From the enterprise perspective, Bojian is still the leader in the MS field. In 2021, MS drug sales total reached $6.096.8 billion, followed by Roche ($4.326 billion), followed by Novartis and Sanofi, with MS drugs totaling $3.44 billion and 2.037 billion euros, respectively.

Given the huge drug market for MS, there are still several potential drugs under development, such as the BTK inhibitor Autinib, Merck’s BTK inhibitor evobrutinib (M2951), and TG Therapeutics’s new glycoengineered anti-CD20 mmab ublituximab.Data from a post-hoc analysis of a phase 2 clinical trial of evobrutinib showed that evobrutinib can affect brain injury related to chronic inflammation in the central nervous system (CNS), becoming the first BTK inhibitor confirmed to significantly reduce slow expanding lesions (SEL).Two phase 3 clinical studies of ublituximab and MS with first-line oral standard of care drug Aubagio for M S reached the primary endpoint: the annualized relapse rate (ARR) was statistically significantly reduced from Aubagio (during 96 weeks of treatment, p


Post time: Feb-14-2022